About Epiontis

Who we are

Epiontis was founded in 2003 by Dr. Sven Olek and Dr. Ulrich Hoffmueller. The company is headquartered in the Science- and Technology Park Adlershof in the south of Berlin, Germany - a leading site for Biotechnology and Life Sciences in Berlin-Brandenburg. Epiontis offers worldwide services.    

What we do

Using a novel molecular diagnostics technology, Epiontis offers an immune cell monitoring service as well as customized development of epigenetic assays. Epiontis' epigenetic assay format allows the identification and quantification of any cell type with accuracy and technical ease. The main field of use is the monitoring of immune cells in research and clinical studies for autoimmune and infectious diseases or cancer. Here, we offer a portfolio of established assays for immune cells. Examples include diagnostic assays for regulatory T cells (Tregs) and tumor infiltrating lymphocytes, with many other epigenetic assays under development. In addition, we develop customized immunmonitoring essays that serve your needs.

Since 2008, Epiontis has developed epigenetic immune cell assays and offered immunomonitoring services for clinical trials. Currently, the company is also establishing diagnostic assays.

  1. Privacy Statement: Your phone number or email address will be exclusively used to contact you and will not be given to any third party.